A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies

Condition:   Advanced or Metastatic Malignancies
Interventions:   Drug: INCAGN01949;   Drug: Nivolumab;   Drug: Ipilimumab
Sponsor:   Incyte Corporation
Not yet recruiting - verified August 2017

http://ift.tt/2uyYJmE